Keeping Track: Vitaros Reenters The Wilderness, Remoxy Gives It A Fourth Try, And Two Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your US product review news for week, in brief: The regulatory nightmare for Apricus Biosciences Inc.'s Vitaros (alprostadil, DDAIP.HCl) is continuing, as it reeled in a complete response letter nearly 10 years after it first received a "not approvable letter" from the US FDA.

Pain Therapeutics Inc., meanwhile, is hoping for light at the end of the tunnel, as the company has refiled...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet